李宁

李宁, listed as board member, has filed trades across 4 companies (mainly through SSE / SZSE (CSRC)), most often in 南微医学, 新锐股份 and 成大生物. We count 6 filings; the first trade dates from 22 December 2021 and the latest from 28 May 2026.

In open-market terms, that means 3 purchases worth €170k on one side and 3 sales worth €307k on the other. Taken together, the sales exceed the purchases by €137k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2026, the count stands at no purchases and 3 sales.

A typical purchase (the median) is worth €63k. 2 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 3 purchases with a full 90-day history, the hit rate stands at 33% and the median 90-day move at -8.2%. This is a record of the past, not a forecast.

The latest filing, published on 28 May 2026, reports an open-market sale of €25k in 新锐股份. The most recent open-market purchase was published on 11 April 2023, 1,286 days ago. Most trades are made public on the day they happen. The shorter that gap, the sooner other investors can see what insiders have done. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.